EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Delivery devices and container closure systems for co-formulated and co-administered biologics

Ming Zhou iD, Kevin Duffy, Chris Mitchener, Galen Huaiqiu Shi, David Collins

Antibody Therapeutics · 29.06.2026 · 9 (3) · 437-448

DOI: 10.1093/abt/tbag034 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antibody Therapeutics, online erschienen am 22.06.2026. Verfasst von Ming Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Delivery Device and Connected Solutions, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46225, USA. Die Arbeit nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The rapid evolution of antibody-based biologics is transforming the management of chronic conditions and driving innovation in drug-delivery devices and container closure systems (CCS). Combination therapy enabled through coformulation or coadministration offers the potential for synergistic outcomes that are not achievable with single-drug products. This review examines development pathways and emerging strategies for delivery devices and CCS that support antibody-biologic coformulations and coadministration, from clinical trials through commercialization. We evaluate established technologies with an emphasis on design and delivery mechanisms, and on key technical considerations, including compatibility with dual-molecule formulations, protein–protein interactions, sterilization approaches, container closure integrity, and human factors in CCS and device design. We also highlight emerging technologies and future opportunities for advancement. Overall, this review provides insights into the challenges and innovations shaping CCS and delivery systems for co-formulated or co-administered antibody biologics.

Schlagwörter

Stichwörter der Autor:innen

biologic combination therapycoadministrationcoformulationcontainer closure systemsdelivery devices

Autor:innen und Institutionen

  • Delivery Device and Connected Solutions, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46225, USA.

ORCID-Profile: Ming Zhou

Förderung

  • Eli Lilly and Company

Zitieren

APA

Zhou, M., Duffy, K., Mitchener, C., Shi, G. H., & Collins, D. (2026). Delivery devices and container closure systems for co-formulated and co-administered biologics. Antibody Therapeutics, 9(3), 437-448. https://doi.org/10.1093/abt/tbag034

Vancouver

Zhou M, Duffy K, Mitchener C, Shi GH, Collins D. Delivery devices and container closure systems for co-formulated and co-administered biologics. Antibody Therapeutics. 2026;9(3):437-448. doi:10.1093/abt/tbag034

BibTeX
@article{Zhou2026,
  author = {Zhou, Ming and Duffy, Kevin and Mitchener, Chris and Shi, Galen Huaiqiu and Collins, David},
  title = {Delivery devices and container closure systems for co-formulated and co-administered biologics},
  journal = {Antibody Therapeutics},
  year = {2026},
  volume = {9},
  number = {3},
  pages = {437--448},
  doi = {10.1093/abt/tbag034}
}
Kostenlos starten →